Phase III clinical trial data of this miracle pill revealed that chances of survival from final stage liver cancer is increased by 44% or about three months life extension.

Final stage liver cancer is deadly and currently patients suffering this condition have no treatment option.

Sorafenib is a pill that directly targets malignant cancer cells and cuts off the blood supply feeding the tumour and has been found in a large scale multinational trial, conducted by researchers from the Mount Sinai School of Medicine in New York and Hospital Clinic of Barcelona (Spain), to work on tumors within the liver and those that have already spread in other parts of the body.

According to Dr Subhash Gupta, head of department, liver surgery, Apollo Hospital:

“Sorafenib holds great promise for patients on whom aggressive options like a mix of surgery, radiation and chemotherapy fail.

Once detected early, liver cancer can be addressed by either a transplant or other techniques.”

Sorafenib is co-marketed by Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals as Nexavar® - which is already indicated for the treatment of advanced renal cell carcinoma (kidney cancer).

Find more details from the full report at India Times and Science Daily.

[hat tip: Kendra James]

Post from: Blisstree

Sorafenib: Miracle Pill for Liver Cancer